NCT07150806 - RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 13, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions

Recurrent Meningioma

Interventions

DRUG

Actinium Ac 225 DOTATATE RYZ101

Given IV

PROCEDURE

Biospecimen Collection

Undergo blood and urine sample collection

PROCEDURE

Computed Tomography

Undergo CT scan

PROCEDURE

Echocardiography Test

Undergo echocardiography

RADIATION

Gallium Ga 68-DOTATATE

Given IV

DRUG

L-lysine/L-arginine-containing Amino Acid

Given IV

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

PROCEDURE

Multigated Acquisition Scan

Undergo MUGA scan

PROCEDURE

Positron Emission Tomography

Undergo PET scan

PROCEDURE

Somatostatin Receptor Positron Emission Tomography

Undergo SSTR PET scan

Trial Locations (1)

43210

RECRUITING

Ohio State University Comprehensive Cancer Center, Columbus

All Listed Sponsors

collaborator

RayzeBio, Inc.

INDUSTRY

lead

Joshua Palmer

OTHER